Vesugen is a synthetic linear tripeptide (Lys-Glu-Asp, one-letter code KED) from the Khavinson family of short-peptide “bioregulators” developed at the St. Petersburg Institute of Bioregulation and Gerontology.1 It is studied as a vascular-tissue regulator, with reported activity centred on endothelial cells.2 The published evidence is limited and almost entirely in vitro or in animal models; no controlled human clinical trials have been verified, and several commonly repeated claims appear only in vendor material rather than peer-reviewed sources. No CAS Registry Number is assigned in PubChem, and no pharmacokinetic or half-life data have been published.3 This page is for research-use-only reference and does not describe any therapeutic use.
Sequence & identity
Linear L-tripeptide; structure and identifiers confirmed against PubChem CID 87571363 (InChIKey LLSUNJYOSCOOEB-GUBZILKMSA-N).3
Mechanisms studied
Khavinson-class short peptides are proposed to act as epigenetic regulators: di-, tri- and tetrapeptides are reported to enter cell nuclei and nucleoli and interact with the nucleosome, histone proteins and single- and double-stranded DNA, including sequence recognition within gene-promoter regions, thereby modulating transcription rather than altering the DNA sequence.1 For KED specifically, researchers report binding of related ultrashort peptides to histones and effects consistent with this template-directed model, but a defined, KED-specific promoter target has not been firmly established in the verified literature.2
Dosing in the research literature
The figures below summarise regimens as reported in published research — they are not recommendations or directions for use.
| Source / model | Regimen reported | Notes |
|---|---|---|
| Ilina et al., 2022 (in-vitro) | Applied to cultured cells in vitro; the review describes ultrashort peptides used at nanomolar-range culture concentrations rather than any administered human dose | Cell-culture exposure only; not a human dosing regimen. |
| Human clinical dosing | Not established | No controlled human clinical-trial dosing for Vesugen has been verified. Vendor “protocols” are not study-derived and are excluded. |
Effects observed in research
In a peer-reviewed review, the KED peptide was reported to contribute to restoration of VEGF expression in aortic endotheliocyte cultures obtained from patients with atherosclerosis, and to have a normalizing effect on capillary-wall state (resistance and permeability) with improved cerebral circulation in models.2 Related work attributes endothelial markers such as Ki-67, Cx43 and normalized endothelin-1 to KED, but these specific endpoints are reported mainly in secondary and bioregulator-literature summaries and should be treated as limited preliminary findings rather than established effects.1 No clinical efficacy in humans has been demonstrated.
Strength of evidence
Evidence grade C. Findings derive from in-vitro endothelial and stem-cell cultures and animal/model studies, largely from a single research group; English-language data are limited and no controlled human trials have been verified.2 Where values could not be confirmed (CAS number, half-life, clinical dosing) they are marked “Not established” rather than estimated.3
Reconstitution & storage
Reconstitute with bacteriostatic water for laboratory handling. Store lyophilised material frozen and reconstituted material refrigerated. Use Peptigo’s reconstitution calculator and storage cheat sheet for working figures.
References
- Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. doi:10.3390/molecules26227053.
- Ilina A, Khavinson V, Linkova N, Petukhov M. Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer’s Disease. International Journal of Molecular Sciences. 2022;23(8):4259. doi:10.3390/ijms23084259.
- PubChem Compound Summary for CID 87571363, Lys-Glu-Asp (lysyl-glutamyl-aspartic acid). National Library of Medicine (US), National Center for Biotechnology Information. Accessed 2026-06-03.